The impact of onabotulinumtoxinA on severe headache days: PREEMPT 56-week pooled analysis

Por Matharu, Manjit, Halker, Rashmi, Pozo-Rosich, Patricia, DeGryse, Ronald, Manack Adams, Aubrey, Aurora, Sheena K.
Publicado no J Headache Pain (2017)

Validation of the Headache Impact Test (HIT-6) in patients with chronic migraine

Por Rendas-Baum, Regina, Yang, Min, Varon, Sepideh F, Bloudek, Lisa M, DeGryse, Ronald E, Kosinski, Mark
Publicado no Health Qual Life Outcomes (2014)

OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine over one year of treatment: Pooled results from the PREEMPT randomized clinical trial program

Por Lipton, Richard B, Rosen, Noah L, Ailani, Jessica, DeGryse, Ronald E, Gillard, Patrick J, Varon, Sepideh F
Publicado no Cephalalgia (2016)

Per cent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT

Por Silberstein, Stephen D, Dodick, David W, Aurora, Sheena K, Diener, Hans-Christoph, DeGryse, Ronald E, Lipton, Richard B, Turkel, Catherine C
Publicado no J Neurol Neurosurg Psychiatry (2015)